Emilia Salzmann-Manrique
Overview
Explore the profile of Emilia Salzmann-Manrique including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fekadu-Siebald J, Salzmann-Manrique E, Heusel J, Willasch A, Hauck F, Gonzalez-Granado L, et al.
Blood Adv
. 2025 Jan;
PMID: 39775668
JAGN1 (Jagunal-homolog1) is a ER-resident transmembrane protein which is part of the early secretory pathway and granulocyte colony-stimulating factor receptor mediated signaling. Autosomal recessively inherited variants in the JAGN1 gene...
2.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann J, Seidl C, et al.
Front Immunol
. 2024 Dec;
15:1413927.
PMID: 39737173
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an...
3.
Graafen L, Heinze A, Albinger N, Salzmann-Manrique E, Ganss F, Hunecke S, et al.
Front Immunol
. 2024 Aug;
15:1377955.
PMID: 39165363
Ataxia telangiectasia (AT) is a rare autosomal-recessive disorder characterized by profound neurodegeneration, combined immunodeficiency, and an increased risk for malignant diseases. Treatment options for AT are limited, and the long-term...
4.
Schmidt A, Stichel D, Salzmann-Manrique E, Konigs C
Hamostaseologie
. 2024 Jul;
44(5):350-357.
PMID: 39009010
During routine treatment, plasma samples of patients with hemophilia A or acquired hemophilia A are frequently analyzed for the presence of FVIII-specific antibodies. While only inhibitory antibodies can be detected...
5.
Heim C, Hartig L, Weinelt N, Moser L, Salzmann-Manrique E, Merker M, et al.
Mol Ther Oncol
. 2024 May;
32(2):200802.
PMID: 38706988
Treatment resistance and immune escape are hallmarks of metastatic rhabdomyosarcoma (RMS), underscoring the urgent medical need for therapeutic agents against this disease entity as a key challenge in pediatric oncology....
6.
Kuci Z, Piede N, Vogelsang K, Pfeffermann L, Wehner S, Salzmann-Manrique E, et al.
J Transl Med
. 2024 Jan;
22(1):39.
PMID: 38195462
Background: According to the definition of the International Society for Cell and Gene Therapy (ISCT), mesenchymal stromal cells (MSCs) do not express HLA-DR. This phenotypic marker as a release criterion...
7.
Barnbrock A, Hamannt F, Salzmann-Manrique E, Rohm T, Lange S, Bader P, et al.
Front Pediatr
. 2023 Dec;
11:1249558.
PMID: 38094191
Introduction: Increasing survival rates after hematopoietic stem cell transplantation (HSCT) in childhood should put focus on improving the quality of life as adults. An essential aspect is fertility and its...
8.
Theis M, Donath H, Woelke S, Bakhtiar S, Salzmann-Manrique E, Zielen S, et al.
Eur J Neurol
. 2023 Aug;
30(12):3842-3853.
PMID: 37540892
Background And Purpose: Ataxia-telangiectasia (A-T) is a rare, autosomal recessive, multisystem disorder that leads to progressive neurodegeneration with cerebellar ataxia and peripheral polyneuropathy. Cerebellar neurodegeneration is well described in A-T....
9.
Tramsen L, Bochennek K, Sparber-Sauer M, Salzmann-Manrique E, Scheer M, Dantonello T, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046711
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma (STS) in childhood. Whereas more than 90% of patients with localized low-risk RMS can be cured, metastatic RMS have a dismal...
10.
Jarisch A, Salzmann-Manrique E, Soerensen J, Sach G, Rettinger E, Willasch A, et al.
Br J Haematol
. 2023 Mar;
201(6):1159-1168.
PMID: 36949601
ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non-malignant diseases, has...